in Biomedical Science from the University of Tennessee at Memphis, subsequently completing a post-doctoral fellowship in Nutritional Biochemistry at the Children's Hospital Oakland Research Institute in Oakland, CA
As NBC News reported, in February, Novo settled two lawsuits against two businesses claiming to offer compounded versions of Ozempic and Wegovy
This marked a turning point, shifting GLP-1 agonists from diabetes-focused therapies to primary obesity treatments
The most common adverse events were gastrointestinal in nature and consistent with other incretin-based drugs
But its benefits extend far beyond cellular health
Similarly, in the AWARD-7 trial, dulaglutide was shown to preserve eGFR more effectively than insulin glargine over 52 weeks in patients with moderate-to-severe CKD, despite similar glycemic control [21]